<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Sustained response to targeted therapies in a patient with pulmonary hypertension owing to Langerhans cell histiocytosis

Simple item page
dc.contributor.authorKaymaz, Cihangir
dc.contributor.authorTanyeri, Seda
dc.contributor.authorKaragöz, Ali
dc.contributor.authorKeskin, Berhan
dc.contributor.authorAkbal, Ozgur Yasar
dc.contributor.authorTokgoz, Hacer Ceren
dc.contributor.authorKültürsayar, Barkın
dc.date.accessioned2026-10-09T21:18:50Z
dc.date.issued2021
dc.departmentYüksek İhtisas Üniversitesi
dc.description.abstractPulmonary hypertension (PH) in association with Pulmonary Langerhans Cell Histiocytosis (PLCH) is an uncommon pulmonary vascular disease classified in group 5 PH according to currently available guidelines for the diagnosis and treatment of PH. Oxygen support, diuretic treatment and lung transplantation are standard therapies for this disease. Generally, pulmonary arterial hypertension (PAH) targeted therapies are not considered to be beneficial in this subgroup of PH.
dc.identifier.doi10.5152/AnatolJCardiol.2021.49500
dc.identifier.endpage668
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue9
dc.identifier.startpage665
dc.identifier.trdizinid489457
dc.identifier.urihttps://doi.org/10.5152/AnatolJCardiol.2021.49500
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/489457
dc.identifier.urihttps://hdl.handle.net/20.500.12794/1107
dc.identifier.volume25
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofThe Anatolian Journal of Cardiology
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TR-Dizin_20260922
dc.subjectGenel ve Dahili Tıp
dc.subjectKalp ve Kalp Damar Sistemi
dc.titleSustained response to targeted therapies in a patient with pulmonary hypertension owing to Langerhans cell histiocytosis
dc.typeArticle

Files

Collections

TR-Dizin İndeksli Yayınlar Koleksiyonu